Trials / Recruiting
RecruitingNCT06897046
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 | PD-1/CTLA-4 |
| DRUG | QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed | PD-1/CTLA4 combined chemotherapy drugs |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2027-02-25
- Completion
- 2027-05-25
- First posted
- 2025-03-26
- Last updated
- 2025-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06897046. Inclusion in this directory is not an endorsement.